Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dasatinib
Drug ID BADD_D00589
Description Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
Indications and Usage For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
Marketing Status Prescription
ATC Code L01EA02
DrugBank ID DB01254
KEGG ID D03658
MeSH ID D000069439
PubChem ID 3062316
TTD Drug ID D0E6XR
NDC Product Code 63285-862; 63285-867; 0003-0855; 63285-863; 63285-866; 63285-865; 68554-0070; 54893-0015; 54893-0047; 0003-0857; 0003-0852; 0003-0527; 0003-0528; 76302-014; 50193-0524; 46708-891; 14778-1313; 62207-973; 63285-864; 0003-0524; 59651-468; 53104-7725
Synonyms Dasatinib | N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | Sprycel | (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | BMS 354825 | 354825, BMS | BMS354825 | BMS-354825
Chemical Information
Molecular Formula C22H26ClN7O2S
CAS Registry Number 302962-49-8
SMILES CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aorta hypoplasia24.03.03.018; 03.07.08.0020.000533%Not Available
Live birth18.08.02.0070.002398%Not Available
Blast crisis in myelogenous leukaemia16.01.08.002; 01.10.08.0020.000417%Not Available
Polymerase chain reaction13.18.01.0100.000533%Not Available
Cytomegalovirus test positive13.08.03.0140.000533%Not Available
Beta haemolytic streptococcal infection11.02.06.0060.000533%Not Available
Corona virus infection11.05.04.0260.000533%Not Available
Clostridium difficile infection11.02.02.0090.002131%Not Available
Peripheral artery occlusion24.04.03.0220.001066%Not Available
Rheumatoid factor increased13.06.01.0190.000799%Not Available
Gastrointestinal oedema07.11.01.0120.000799%Not Available
Colitis erosive07.08.01.0180.000533%Not Available
Right ventricular systolic pressure increased13.14.02.0210.001598%Not Available
Klebsiella infection11.02.03.0030.000799%Not Available
Blast cell count increased13.01.03.0080.000533%Not Available
Leukaemia recurrent16.01.03.005; 01.10.03.0050.000417%Not Available
Gene mutation identification test positive13.22.03.0010.000799%Not Available
Acute lymphocytic leukaemia recurrent01.10.01.003; 16.01.01.0030.000834%Not Available
Graft versus host disease in skin23.07.04.025; 12.02.09.031; 10.02.01.0620.000533%Not Available
Central nervous system leukaemia17.02.10.019; 16.01.03.004; 01.10.03.0040.000139%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000799%Not Available
Chronic myeloid leukaemia transformation16.01.07.004; 01.10.07.0040.000278%Not Available
Foetal hypokinesia18.03.02.0150.000533%Not Available
Natural killer cell count increased13.01.06.0580.001598%Not Available
Acquired gene mutation08.01.10.0020.001598%Not Available
Infectious pleural effusion22.05.01.004; 11.01.09.0110.000799%Not Available
Spinal pain15.02.01.008; 08.01.08.030; 17.10.01.0200.000533%Not Available
Chronic myeloid leukaemia recurrent16.01.07.003; 01.10.07.0030.000533%Not Available
Graft versus host disease in gastrointestinal tract12.02.09.028; 10.02.01.059; 07.11.01.0270.000139%Not Available
Internal haemorrhage24.07.01.0720.001598%Not Available
The 29th Page    First    Pre   29 30    Next   Last    Total 30 Pages